Eli Lilly Sets Early 2027 Filing Date for Retatrutide After Two More Successful Trials
Eli Lilly announced this week that it plans to submit retatrutide, its next-generation obesity treatment, for regulatory approval during theโฆ
Read Alert โ
All our latest penny stock alerts, analysis, and market research in one place.
Eli Lilly announced this week that it plans to submit retatrutide, its next-generation obesity treatment, for regulatory approval during theโฆ
Wall Street’s Fear Gauge Still Flashing Warning Signs as Middle East Conflict Weighs on Markets U.S. stocks may have furtherโฆ
Middle East conflict has disrupted one of the world’s most critical oil shipping lanes, sending crude prices to their biggestโฆ
BMO Capital Markets is calling Okta one of the early beneficiaries of the agentic AI boom โ raising its priceโฆ
Synopsys is attracting some of the most powerful forces in the market at once โ a strategic investment from Nvidia,โฆ
A successful software sector trade is now closed. But one stock inside the IGV ETF is flashing a high-conviction shortโฆ